ArticlePeerJ2025
Effect of major ozone autohemotherapy in fibromyalgia syndrome: a retrospective study.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Major ozone therapy improves disease severity without affecting retinal microvascular parameters in fibromyalgia syndrome: an observational pre-post study.Rheumatology international · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibromyalgia Syndrome (FMS) is a multifaceted chronic disease characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, cognitive dysfunction, and increased sensitivity to stimuli, commonly referred to as central sensitization. Ozone therapy is currently used in the treatment of many chronic diseases by creating controlled oxidative stress. This study aimed to evaluate the effects of major autohemotherapy (MAH) on pain, quality of life, functional status, and sleep quality in patients with FMS. Methods: A total of 72 patients who underwent 10 sessions of MAH between April 1, 2023 and September 1, 2023 were included in this retrospective study. A total of 10 sessions of major ozone therapy were applied to the patients, two sessions per week. In the first session, a total of 1,000 mcg of MAH (100 ml at 10 mcg/ml) was administered. In the following sessions, the concentration was gradually increased by 5 mg/ml at each session reaching up to 30 mcg/ml with a maximum cumulative dose of 3,000 mcg. Pre-and post-treatment pain status of the patients was evaluated with the Visual Analog Scale (VAS), functional status with the Fibromyalgia Impact Questionnaire (FIQ), quality of life with the Short Form-36 (SF-36), and sleep status with the Pittsburgh Sleep Quality Index (PSQI). Results: The mean age of 68 female and 4 male patients included in the study was determined as 54.17 ± 11.17. VAS was determined as 7.76 ± 2.01 before treatment and 4.77 ± 2.20 after treatment. FIQ score was determined as 69.08 ± 16.01 before treatment and 56.18 ± 22.46 after treatment, Pittsburg Sleep Quality Index score was determine as 10.27 ± 3.37 before treatment and 9.61 ± 2.81 after treatment. Statistically significant differences were found in VAS, FIQ, SF-36, and PSQI values before and after treatment ( Conclusion: According to the study results, MAH has been found to provide significantly positive effects in reducing pain intensity, improving functional status, enhancing quality of life, and improving sleep patterns in individuals diagnosed with fibromyalgia syndrome. Considering the low side effect profile and positive clinical results of MAH in fibromyalgia patients resistant to other treatment methods, it is recommended that this method be considered as a complementary or alternative treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.